WEDI to HHS: More ICD-10 testing needed

The Workgroup for Electronic Data Interchange (WEDI) has submitted a letter to the Department of Health & Human Services (HHS) Secretary encouraging the agency to consider additional Medicare testing prior to ICD-10 implementation.

WEDI has been working with public and private sectors of the industry to facilitate implementation of ICD-10 and believes the magnitude of the change warrants thorough testing with a range of trading partners to avoid significant disruption to the industry.

“Complete end-to-end testing of any technology project allows developers to ensure, as much as possible, that when the individual parts are put together, the system works as expected. IT experts concur that adequate end-to-end testing vs. testing individual steps and processes in isolation is critical to successfully implementing any major IT project,” the letter reads.

Read the complete letter.

 

Complete end-to-end testing of any technology project allows developers to ensure, as much as possible, that when the individual parts are put together, the system works as expected. IT experts concur that adequate end-to-end testing vs. testing individual steps and processes in isolation is critical to successfully implementing any major IT project.  - See more at: http://www.wedi.org/knowledge-center/comment-letters-testimony/comment-letters/2014/01/13/wedi-icd-10-testing-concerns#sthash.DrWT5ZQY.dpuf
Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.